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Abstract 15 
Evaluation of bone health in childhood is important to identify children who have inadequate 16 
bone mineralisation and who may benefit from interventions to decrease their risk of 17 
osteoporosis and subsequent fracture. There are no bone protective agents that are 18 
licensed specifically for the prevention and treatment of osteoporosis in children. In this 19 
review we discuss the mechanism of action and use of bisphosphonates and other new and 20 
established bone protective agents in children.  21 
 22 
Introduction 23 
Healthy bone is metabolically active and undergoes continuous modelling and remodelling 24 
during childhood to maintain the balance between bone formation and bone resorption. The 25 
size and shape of the skeleton changes rapidly during modelling in childhood and 26 
adolescence and approximately 90% of bone mass is accrued during the first 18 years of 27 
life1.   If this finely tuned process is disturbed, then osteoporosis can result. Osteoporosis is 28 
 2 
defined as a skeletal disorder characterised by compromised bone strength and 1 
predisposing a person to an increased risk of fracture2 and the importance of correctly 2 
diagnosing osteoporosis in children has been highlighted by the International Society for 3 
Clinical Densitometry (ISCD) 3. The finding of one or more vertebral fracture is indicative of 4 
osteoporosis in the absence of local disease or high energy trauma. In the absence of 5 
vertebral compression, a diagnosis of osteoporosis is indicated by the presence of both a 6 
clinically significant fracture history and bone mineral density (BMD) z-score ≤ 2.03. Skeletal 7 
fragility in children may be primary, due to an intrinsic bone abnormality (usually genetic in 8 
origin) or secondary as a result of an underlying medical condition or its treatment. 9 
Examples of conditions that can result in primary skeletal fragility include osteogenesis 10 
imperfecta, idiopathic juvenile osteoporosis and osteoporosis pseudoglioma syndrome. In 11 
most but not all cases, this skeletal fragility is associated with reduced bone mineral density 12 
and will also satisfy the ISCD definition of osteoporosis. Secondary osteoporosis is more 13 
common and has been reported in several chronic conditions in children. It may arise due to 14 
a combination of factors including the inflammatory process itself, sub-optimal nutrition, 15 
reduced lean body mass, decreased physical activity, delayed puberty or due to treatment 16 
for the underlying condition, particularly glucocorticoids (GC)4. 17 
 18 
Although there are several bone-protective agents currently used in adults with 19 
osteoporosis, none are licensed specifically for the prevention or treatment of osteoporosis 20 
in childhood. For children with chronic illness, treatment of the underlying condition should 21 
be the mainstay of osteoporosis prevention and treatment.  22 
 23 
Bisphosphonates   24 
In children, bone protective therapy has often been delivered using anti-resorptive therapy, 25 
and in particular, bisphosphonates (BPs). Because a detailed review of the use of BPs in 26 
every chronic childhood condition is not possible within this article, we will focus on three 27 
examples:  28 
 3 
1. Osteogenesis Imperfecta (OI) - an example of primary skeletal fragility 1 
2. Cerebral palsy- secondary osteoporosis related to immobility 2 
3. Duchenne Muscular Dystrophy- secondary osteoporosis associated with GC use. 3 
Bisphosphonates were the first pharmacological agent to be used in children with fragility 4 
fractures5. Although BPs have now been widely used in adults with a range of conditions, 5 
their use in children has been more limited, in part because of concerns regarding the 6 
effects on the growing skeleton6. They are so called because they have two phosphonate 7 
groups, which enable them to bind to bone. They reduce osteoclast activity primarily by 8 
promoting osteoclast apoptosis and so inhibiting bone resorption. BPs also reduce overall 9 
bone turnover because bone resorption is coupled to bone formation. However, because 10 
osteoblast activity at the periosteal surface is unaffected, an overall increase in bone 11 
formation in the growing skeleton and potential re-shaping of existing vertebral fractures can 12 
still occur, despite the low turnover state7. The newer, nitrogen-containing BPs (e.g. 13 
alendronate, zoledronate, risedronate and pamidronate) work by inhibiting the enzymes 14 
within osteoclasts that are involved in the farnesyl pyrophosphate synthase and mevalonate 15 
pathways, which are important for varying aspects of osteoclast function and also inducing 16 
osteoclast apoptosis7. Although they have poor oral absorption, BPs have an extremely long 17 
half-life; a study of pamidronate in paediatric OI found that 2 years after cessation of 18 
treatment, bone mineral content (BMC) z-scores remained above pre-treatment levels8 and 19 
urinary excretion of pamidronate has been detected up to 8 years later9.  This has potential 20 
implications for females of reproductive age as rodent studies have shown that BPs can 21 
cross the placenta and accumulate in the fetal skeleton causing decreased bone growth and 22 
deaths in the offspring10. There is, however, no evidence to date that prior BP exposure or 23 
even BP exposure during pregnancy is associated with reproductive toxicity11. 24 
 25 
1. Osteogenesis Imperfecta (OI) 26 
BPs were first used in children to treat OI (the most common primary disorder of bone 27 
fragility) in 198712 and are now the mainstay of treatment in this condition. The main 28 
 4 
effect of BPs in children with OI appears to be an increase in cortical bone width (a 1 
growth-dependent process that in turn improves mechanical strength) and trabecular 2 
number. The primary aim of BP treatment in OI is to reduce fracture frequency. Despite 3 
there being some evidence from a recent Cochrane review13 that included 14 studies and 4 
819 participants to show that either oral or cyclical intravenous (IV) BPs increase bone 5 
mineral density in children with OI, the authors were unable to demonstrate reliable 6 
evidence of improvements in overall clinical status (reduced pain, improved growth or 7 
functional mobility). Also, whilst several studies independently reported a decreased 8 
fracture risk, the review could not show a consistent reduction in fracture rate after use of 9 
either oral or IV BP. There is growing interest in the use of oral BPs in OI, particularly in 10 
those with milder phenotypes, as they may be more cost-effective and easier to use than 11 
IV alternatives1415. As yet, there does not appear to be sufficient evidence to favour oral 12 
agents above IV BPs in the acute treatment phase or in those with severe OI16, although 13 
they may have a role during the maintenance phase.  14 
 15 
2. Secondary osteoporosis  16 
Although BPs are now used for bone protection in many other childhood conditions, much 17 
of the justification for their use in other chronic diseases has been extrapolated from 18 
evidence in OI. A systematic review has concluded that there is insufficient evidence to 19 
recommend BPs as standard therapy for secondary osteoporosis in children because the 20 
link between increasing BMD and reducing fracture risk remains unproven17. The efficacy 21 
of BP therapy on BMD appears to depend on the age at time of treatment and the amount 22 
of bone growth remaining. Generally, they appear to be a safe and effective therapy in 23 
cases of severe bone loss, although the long-term effect of inhibition of bone turnover 24 
remains unknown.  BPs may also ameliorate pain in certain circumstances18 but further 25 
work is needed to clarify this5.  26 
 BPs in Cerebral Palsy (CP) 27 
 5 
CP is a heterogeneous group of non-progressive disorders of motor function and posture. 1 
Some patients with CP have a significant reduction in mobility and bone mass quickly 2 
diminishes without adequate bone loading. By 10 years of age, over 95% of those with non-3 
ambulatory severe CP have osteopaenia19 and fractures are 20% more likely  in those who 4 
are non-ambulatory. First line measures should include optimising vitamin D and calcium 5 
levels and the encouragement of weight bearing activity. Vibration therapies have also been 6 
used, although there is only limited evidence of their effectiveness.  A recent meta- 7 
analysis20 assessing the effect of BPs on increasing BMD in children with CP found that the 8 
lumbar spine and femoral BMD z-scores were significantly higher after BP treatment 9 
compared with pre-treatment values, but only 1 randomised controlled trial (RCT) met the 10 
inclusion criteria. Furthermore, it remains unclear whether this translates to a reduction in 11 
fracture incidence, which is important when the annual fracture incidence in children with 12 
moderate to severe CP is 4%21. In addition, oromotor dysfunction and gastro-oesophageal 13 
reflux are often present in CP which may preclude the use of oral BPs.  14 
 BPs in Duchenne Muscular Dystrophy (DMD) 15 
Long term GC use has dramatically improved the disease course in DMD22. GC are 16 
normally commenced once muscle function begins to plateau, usually at about 5 years of 17 
age and are continued through to adulthood. Growth retardation23 and fragility fractures 18 
are important problems in DMD; it is predicted that after 100 months of GC therapy, 75% 19 
of boys will sustain a vertebral fracture24.  Although BPs are frequently used, there is no 20 
consensus regarding timing of initiation, drug regimen or cessation of treatment. 21 
Prophylactic BP in DMD in those receiving GC has been reported to be associated with 22 
increased survival25. Whilst BPs may be associated with an improvement in back pain 23 
and some vertebral re-shaping, provided that the child is still growing, they do not 24 
completely prevent the development of new vertebral fractures26. Recent data from trans-25 
iliac biopsies in boys with DMD have also shown that whilst BPs appear to be effective 26 
early in GC-induced bone loss, long term use may further dampen remodeling27. A recent 27 
Cochrane review concluded that there was no strong evidence to guide the use of any 28 
 6 
therapy to prevent or treat GC-induced osteoporosis in boys with DMD28. Therefore, 1 
before considering prophylactic BP use, the potential risks must be weighed up against 2 
the benefits including consideration of the potential adverse effects of BP therapy and a 3 
decision made regarding the most appropriate time to use them29.  4 
 5 
Adverse effects of bisphosphonate therapy  6 
BPs are generally well tolerated in children30, but as little is known of the long-term 7 
consequences of BP treatment, all patients should be regularly reviewed, looking in 8 
particular for evidence of adverse effects.  An acute phase response to the initiation of IV 9 
BP therapy is very common, with short-lived fever and flu-like symptoms. 10 
Hypophosphataemia and hypocalcaemia can also occur31.  Delayed bone healing after 11 
osteotomy in OI has also been described with BP use32. There are also three rare, but 12 
potentially serious adverse events that may be related to longer-term exposure to BPs: 13 
a) Osteonecrosis of the jaw 14 
BP-associated osteonecrosis of the jaw (ONJ) is defined as, “an area of exposed bone in the 15 
maxillofacial region that does not heal within 8 weeks, in a patient who is receiving or has 16 
been exposed to a BP and has not had radiation therapy to the craniofacial region33”. ONJ 17 
appears to be more common in adults using IV BPs34, and it has not yet been reported in a 18 
child35. Most cases have been documented in those receiving doses higher than prescribed 19 
for osteoporosis (e.g. for malignancy) and in patients on therapy for more than two years. 20 
Experts have suggested doing any invasive dental procedures before starting treatment or 21 
suspending therapy for three or more months before and after such procedures, where 22 
possible36, although there is no evidence to support these recommendations.  23 
b) Atypical femoral fractures 24 
Although atypical sub-trochanteric femur fractures (AFF) are very rare and account for less 25 
than 1% of all hip/ femoral fractures, they have been predominantly reported in patients 26 
taking BPs37 and have recently been associated with BP use in a child38.  Because BPs act 27 
by reducing bone turnover, it is possible that by preventing remodelling and effectively 28 
 7 
‘freezing’ the skeleton, they allow tiny cracks to form and stress fractures to develop. AFFs 1 
occur at sites of high tensional stress, such as the lateral cortex of the proximal femoral 2 
shaft. It is also thought that those taking concomitant GCs in addition to BPs or with a 3 
genetic disposition to fracture may have a further increased risk. A large Swedish 4 
observational study of  femoral fractures in post-menopausal women39 showed that fracture 5 
rate decreased rapidly after drug withdrawal,  therefore intermittent use may be favourable 6 
and a BP ‘holiday’ in children on long term BPs could be considered. 7 
c) Iatrogenic osteopetrosis 8 
In 2003, the first case of BP-induced osteopetrosis (or marble bone disease) was described 9 
in a 12-year-old boy who had received pamidronate infusions for the previous 3 years for 10 
idiopathic bone pain and osteopaenia40.  Abnormal over-suppression of bone remodelling 11 
(with a histological absence of osteoclasts on bone surfaces) was still present when he was 12 
followed up 7 years after cessation of BP.  13 
 14 
Vitamin D and calcium  15 
Vitamin D is essential for skeletal health and regulates calcium absorption41. Vitamin D 16 
deficiency may be  associated with decreased BMC and increased risk of rickets42. 17 
Children with chronic diseases are more prone to vitamin D deficiency for a variety of 18 
reasons including malabsorption, limited sunlight exposure, nutritional restrictions and the 19 
use of medications such as anti-convulsants and GCs, therefore prevention of vitamin D 20 
deficiency should be routinely considered in those with chronic illnesses. The mean 21 
dietary intake of vitamin D in children may only be about 100IU/day43 and therefore in the 22 
UK, the Scientific Advisory Committee for Nutrition has recommended a reference 23 
nutrient intake (RNI) of 400IU per day for children.43 This requirement may be even higher 24 
in those with chronic illnesses44.  Adequate dietary calcium to meet the RNI should also 25 
be advised and supplementation considered if this is unlikely to be reached. There is no 26 
clear evidence that calcium supplementation in excess of the RNI has additional benefits 27 
on bone density whilst there are significant associated risks of excessive total calcium 28 
 8 
intake. Vitamin D and calcium levels should be optimized prior to the initiation of BP 1 
therapy to prevent BP-induced hypocalcaemia and maximize efficacy. 2 
 3 
Growth Hormone (GH) and Insulin-like growth factor (IGF-1) 4 
Whilst there is ample evidence that the GH-IGF-1 pathway has direct effects on bone mass 5 
and strength in experimental models45 the effect of recombinant human GH (rhGH) on bone 6 
health in children is debatable46. In addition to a direct effect on osteoblast activity, it is 7 
possible that the anabolic effects of rhGH may also be mediated through an effect on lean 8 
mass47, alterations in PTH sensitivity48 or even modulation of the 11 beta hydroxysteroid 9 
dehydrogenase shuttle, which is responsible for the inactivation of cortisol to cortisone49. 10 
Given that both rhGH and rhIGF-1 are licensed for use in children with growth disorders and 11 
in light of data from children and adults with chronic inflammation, there is potential for these 12 
anabolic agents to improve growth potential, muscle strength and bone mass in many cases 13 
of primary and secondary osteoporosis. However, before using these pharmacological 14 
agents for this purpose, an improved understanding of their effects on linear growth and 15 
bone mass, and the underlying mechanisms through which they exert their effects on bone, 16 
is imperative.  17 
 18 
Recombinant parathyroid hormone (PTH) 19 
Teriparatide is a form of recombinant human PTH and is unique because unlike BPs, it 20 
stimulates new bone formation.  It is approved for use in adults with osteoporosis and over 21 
half a million adults with severe osteoporosis have received this drug50. Furthermore, its 22 
anabolic effect on bone has opened up the possibility of using it in combination or 23 
sequentially with anti-resorptive agents such BPs51. However experimental studies have 24 
shown that almost half of the rats exposed to the highest doses developed osteosarcoma52. 25 
Despite there being many differences which make humans less susceptible than rats53, this 26 
risk is still of particular concern to the paediatric and adolescent population where 27 
osteosarcoma is most prevalent. However, over the last decade, there have been increasing 28 
 9 
reports of the use of recombinant PTH for intractable hypocalcaemia associated with 1 
hypoparathyroidism in children54.  2 
Sex steroids 3 
Growth and pubertal development are often impaired in chronic disease and the pubertal 4 
process and associated GH surge are vital to increase bone size and bone mineral accrual. 5 
Androgen deficiency is a recognised risk factor for osteoporosis and fracture and evidence 6 
suggests that early initiation of androgen therapy is associated with improved BMD in 7 
adults55. However, precocious puberty or treatment with high doses of either oestrogen or 8 
testosterone can paradoxically cause premature fusion of the epiphyses and a subsequent 9 
reduction in final height56. Oxandrolone, an anabolic steroid that is only weakly androgenic 10 
and does not aromatise, has been studied in children with severe burns. It has been 11 
reported to increase bone mass57 but is often not readily available.. Physiological oestrogen 12 
replacement given transdermally, (so not to inhibit IGF-1 production) alongside cyclical 13 
progesterone has also been shown to increase bone mineral accrual in teenagers with 14 
anorexia58 and the American College of Sports Medicine recommends that oral 15 
contraceptives be considered in amenorrheic athletes over 16 years of age if BMD is 16 
declining despite sufficient weight gain59.  17 
 18 
Alternative agents for consideration 19 
 RANKL inhibitors 20 
Denosumab is a monoclonal antibody to the receptor activator of nuclear factor-kB ligand 21 
(RANKL), a key mediator of osteoclast activity. It is given subcutaneously and targets the 22 
RANKL, (Figure 1), thus inhibiting osteoclast-mediated bone resorption and increasing BMD. 23 
There is extensive data to show its efficacy in postmenopausal osteoporosis60 and it has 24 
also been used in a group of children with OI61. However, its efficacy and side-effect profile 25 
is not clearly understood in children and there may be an increased risk of calcium 26 
dysregulation, so further studies are warranted62.  27 
 28 
 10 
 Sclerostin antibody 1 
Sclerostin is produced by osteocytes (Figure 1) and probably acts as antagonist of the Wnt 2 
signaling pathway to inhibit bone formation, although the exact mechanism remains 3 
unclear63.  Neutralisation of sclerostin using monoclonal antibodies in a mouse model of OI, 4 
resulted in improved bone mass and reduced long bone fragility64 and early clinical studies 5 
in adults have shown similar results65. Sclerostin antibodies have also been used to prevent 6 
GC-induced trabecular and cortical bone loss in mouse models of GC-induced 7 
osteoporosis66. 8 
 9 
 Cathepsin K inhibitors   10 
Cathepsin K is a cysteine protease that is highly expressed by osteoclasts and degrades 11 
type 1 collagen67,  (Figure 1). Cathepsin K inhibitors are thought to reduce bone resorption 12 
whilst also increasing the number of cells of osteoclast lineage and therefore not 13 
suppressing bone formation to the same degree as BPs. Cathepsin K inhibitors such as 14 
odanacatib have shown promising efficacy data68, but an increased risk of atrial fibrillation 15 
and stroke in adult phase 3 trials has meant that marketing of these agents has now been 16 
halted.  17 
 18 
Conclusion  19 
Alongside consideration of pharmacological approaches to maximise bone accrual, 20 
optimising nutritional factors and encouraging activity, within the constraints of the disease 21 
process are also important. Timely pubertal assessment should be performed in those with 22 
chronic disease and where appropriate, puberty induced. Optimal management includes 23 
regular screening to identify those at risk of fracture and then aiming to treat earlier, rather 24 
than waiting for fragility fractures to occur, particularly in those who have little potential for 25 
spontaneous recovery.   26 
 27 
There is still limited evidence for the use of bone protective agents in most childhood 28 
 11 
conditions and although BPs are commonly used, evidence for their efficacy remains limited.  1 
Most studies are small and only have limited follow up and there is no consensus on the 2 
length of BP treatment regimens and dosage in children. Long term safety needs to be 3 
assessed by large scale trials with extended follow-up; the rarity of many the conditions 4 
under study may necessitate international collaborative efforts. Many studies also use 5 
change in BMD as primary outcome but the extent of correlation with this and subsequent 6 
fracture rate remain unclear and age-appropriate reference ranges are not commonly 7 
available for very young children. As anti-resorptives result in a low bone-turnover state with 8 
an associated reduction in bone formation and hence reduced overall bone remodeling it 9 
would clearly be advantageous to find safe and effective anabolic agents to use in the 10 
paediatric population, either alone or in combination and this must remain a research 11 
priority.  12 
 13 
Figure 1 Schematic diagram to show the mechanism of action of bone protective agents. 14 
Bisphosphonates (BP) act at the osteoclast to reduce bone resorption. Recombinant 15 
parathyroid hormone (PTH) eg teriparatide promotes bone formation. Sclerostin is secreted 16 
by osteocytes; sclerostin antibody binds to circulating sclerostin and so enables Wnt 17 
signaling of osteoprogenitors and osteoblasts. RANKL antibodies (eg denosumab) target the 18 
RANK ligand and prevent bone resorption at the osteoclast. Cathepsin K inhibitors (eg 19 
odanacatib) prevent release of enzymes that degrade collagen at the osteoclast.  20 
 12 
Table 1. Examples of conditions associated with skeletal fragility and/or osteoporosis 1 
in children 2 
 3 
Primary: the result of a specific condition 
(usually genetic in origin) causing increased 
skeletal fragility 
Secondary: the result of a medical condition or 
medication used to treat it (children with chronic 
illness often have multiple risk factors) 
 
 Osteogenesis Imperfecta  Medications e.g. glucocorticoids used in 
asthma, arthritis, Duchenne Muscular 
Dystrophy 
 Idiopathic juvenile osteoporosis  Nutritional problems e.g. Crohns, Anorexia 
nervosa 
 Osteoporosis pseudoglioma syndrome  Reduced mobility e.g. Cerebral palsy and 
neuromuscular conditions 
  Conditions causing delayed puberty or 
insufficient production of sex hormones 




 Table 2. Drugs that are used in children and their mechanism of action  1 
Agents that have been used in clinical 
practice in children and may have a 
beneficial effect on bone health: 
Main Mechanism of action 
 
Vitamin D and calcium 
 
Vitamin D regulates calcium absorption which is main mineral 




Reduce osteoclast activity so inhibiting bone resorption. Also 












Oestrogen decreases osteoclast number and activity so reducing 
resorption. Also increases GH levels, which is anabolic to bone 
 
Stimulates osteoblast and pre-osteoblast proliferation directly and 
also indirectly through IGF-1 to increase bone formation. Also 
stimulates osteoclast differentiation, so overall increases bone 
remodeling 
 
Enhances Wnt-dependent activity and increases both osteoblast 
proliferation and osteoblast differentiation 
 
New therapies that are not in clinical 
practice in children but may have a 
beneficial effect on bone health  
 
 
Cathepsin K inhibitors 
 









Prevents antagonism of Wnt signalling pathway so promotes bone 
formation 
  
Teriparatide (Recombinant parathyroid 
hormone) 
Stimulates new bone formation when given intermittently, but is 
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